BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 04, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Panvax: Phase II data

CSL Ltd. (ASX:CSL), Melbourne, Australia
Product: Panvax ( Influenza A/H1N1 2009 vaccine) ( CSL425)
Business: Infectious
Molecular target: NA
Description: Swine influenza A (H1N1) vaccine
Indication: Vaccinate against swine influenza A (H1N1) virus...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >